Benefits
90% of participants achieved >5% weight loss
Published 12-week clinical study in 50 overweight/obese subjects (26 women, ages 25-55): 90% of participants in the GarCitrin group (LeanGard-formulated) achieved more than 5% reduction in body weight, while no one in the placebo group achieved this. The 5% body weight reduction threshold is clinically meaningful — associated with metabolic and cardiovascular health improvements.
Lean body mass increase + body fat reduction
12-week double-blind study comparing GarCitrin (500 mg HCA calcium salt + 25 mg garcinol) vs HCA alone in 46 overweight women (BMI >25): GarCitrin group showed statistically significant decreases in body weight and fat content, AND statistically significant INCREASES in lean body mass and total body water vs both baseline and HCA-alone group. Body recomposition focus — not just weight.
Reduced appetite levels
Same trial documented significantly reduced perceived appetite levels in the GarCitrin group vs both baseline and HCA-only group. Appetite reduction supports sustained weight management vs willpower-based dietary restriction. Particularly valuable for those who struggle with hunger-driven overeating.
Garcinol enhances HCA bioavailability
Garcinia indica garcinol enhances the biological action of HCA — addressing the long-standing problem of poor HCA bioavailability in the cytosol of target cells (one of the primary reasons earlier HCA clinical studies showed mixed results). The combination is MORE potent than HCA alone in weight loss per the head-to-head comparison.
Antioxidant activity contribution
Garcinol is a polyisoprenylated benzophenone with documented antioxidant activity — emulsified garcinol suppresses superoxide anion similarly to DL-alpha-tocopherol (vitamin E). Garcinol is also known for anticarcinogenic and antimicrobial activity. The antioxidant component complements the metabolic weight management mechanisms.
Body mass index improvement
GarCitrin promoted reduction in body mass index (BMI) alongside body fat reduction and lean body mass increase. BMI is the standard population-level obesity classification marker. Combined with the body recomposition effects, GarCitrin addresses both BMI categorization and body composition quality.
ATP citrate lyase inhibition mechanism
(-) HCA competes with citrate for the enzymatic activity of ATP citrate lyase in the cytoplasm — a key enzyme in lipogenesis (fat synthesis). Inhibition reduces acetyl-CoA formation from citrate, decreasing fatty acid and cholesterol synthesis. HCA has 100× greater affinity for citrate lyase than citrate itself per published research.
Indian culinary traditional use
Garcinia cambogia (Malabar tamarind, brindall berry) and Garcinia indica (kokum) have history of traditional culinary use in India — kokum is a common souring agent in Western Indian cuisine. The dietary traditional use supports general safety profile and provides cultural authenticity for Ayurvedic-positioned formulations.
Mechanism of action
ATP citrate lyase inhibition (HCA mechanism)
(-) HCA competes with citrate for ATP citrate lyase — the enzyme converting citrate to acetyl-CoA in the cytoplasm. Acetyl-CoA is the major precursor of fatty acids and malonyl-CoA. Inhibiting citrate lyase reduces fatty acid synthesis and lipid accumulation. HCA has 100× greater affinity for citrate lyase than citrate.
Garcinol bioavailability enhancement
Garcinol enhances the biological action of HCA by improving its bioavailability in the cytosol of target cells. The mechanism addresses the long-standing issue with HCA supplementation — poor intracellular delivery limits efficacy. Garcinol's lipophilic nature may support membrane transport of HCA.
Antioxidant superoxide scavenging
Garcinol scavenges superoxide anion similar in potency to DL-alpha-tocopherol (vitamin E). Antioxidant activity may support metabolic health beyond pure weight management — oxidative stress contributes to insulin resistance and metabolic dysfunction. Multi-mechanism approach beyond single-pathway intervention.
Appetite modulation
HCA affects appetite via mechanisms not fully characterized — may involve serotonergic effects (relevant for carbohydrate cravings) plus signaling from satiety pathways. The clinical appetite reduction documented in trials translates to easier dietary compliance and reduced caloric intake.
Lean body mass preservation
Unlike pure caloric restriction that typically loses both fat and lean mass, GarCitrin specifically increases lean body mass while reducing body fat. The body recomposition effect is uncommon for weight loss supplements — most produce weight loss but body composition is mixed. Maintaining lean mass supports metabolism and physical function during weight loss.
Clinical trials
Double-blind 12-week clinical study comparing GarCitrin (500 mg calcium salt HCA + 25 mg garcinol) vs HCA alone (500 mg calcium salt HCA only). Designed to demonstrate garcinol's bioavailability enhancement contribution. Foundational trial for GarCitrin's commercial positioning.
46 overweight female volunteers (BMI >25). 12-week double-blind intervention.
GarCitrin group: statistically significant decreases in body weight, fat content, and BMI; statistically significant INCREASES in lean body mass and total body water; significantly reduced perceived appetite levels vs both baseline and HCA-only group. Established garcinol enhancement of HCA mechanism and the body recomposition effect that distinguishes GarCitrin from generic HCA products.
12-week randomized placebo-controlled clinical trial of LeanGard (proprietary blend including GarCitrin) at 500 mg/day vs placebo in overweight and obese subjects. Conducted by researchers led by Noor Khan, MD, from Shifaa Hospital in Bangalore, India.
50 overweight and obese subjects (26 women, ages 25-55). 12-week intervention.
90% of participants in the LeanGard group achieved more than 5% reduction in body weight, while NO ONE in the placebo group achieved this weight loss threshold. The 5% weight loss threshold is clinically meaningful — associated with metabolic and cardiovascular health improvements. Established LeanGard (GarCitrin-based) as clinically effective for weight management.
Sabinsa was granted US Patent #7,063,861 for the GarCitrin ingredient. Patent covers the specific composition combining HCA with garcinol from Garcinia species. The patent reflects the unique synergistic combination distinguished from generic Garcinia cambogia/HCA products. Part of Sabinsa's portfolio of 21 US patents and 7 international patents.
Not applicable — patent grant for the GarCitrin composition.
Patent grant recognizes the novel synergistic combination of HCA and garcinol. The intellectual property protection supports commercial differentiation in the crowded weight management category. GarCitrin distinguished from generic HCA products that have inconsistent clinical evidence. The patent supports the body recomposition mechanism beyond simple weight loss.